Home / Deep Research / Methanol Poisoning

Methanol Poisoning

1. Disease Information

2026-07-10
Claude Code MONDO:0017860 Model: claude-haiku-4-5-20251001, claude-opus-4-8 19 citations

1. Disease Information

Overview. Methanol (methyl alcohol, wood alcohol, CH₃OH; CHEBI:17790) poisoning is an acute toxic syndrome resulting from ingestion, inhalation, or dermal absorption of methanol. Methanol itself is only mildly intoxicating (similar to ethanol), but it is oxidized in the liver to formaldehyde and then to formic acid/formate, the metabolite responsible for the characteristic delayed high-anion-gap metabolic acidosis, visual toxicity (potentially irreversible blindness), basal-ganglia injury, and death (StatPearls NBK482121; Liesivuori & Savolainen 1991, Pharmacol Toxicol). A hallmark clinical feature is a latent period of ~12–24 hours between ingestion and symptom onset, corresponding to the time needed to accumulate formate.

Key identifiers. - MONDO: MONDO:0017860 (methanol poisoning) — MalaCards - ICD-10-CM: T51.1 ("Toxic effect of methanol"), with subcodes for accidental (T51.1X1), intentional self-harm (T51.1X2), assault (T51.1X3), undetermined (T51.1X4) — ICD10Data - ICD-11: NE61 (toxic effect of alcohol category); specific code for methanol under harmful effects of substances. - Orphanet: ORPHA:31825 - UMLS: C0392621 - MeSH: "Methanol" (D000432) with subheading /poisoning; "Alcohols" toxicity tree. - Toxic agent: methanol — CHEBI:17790; toxic metabolite formate — CHEBI:15740 (formic acid CHEBI:30751).

Synonyms: methyl alcohol poisoning, wood alcohol poisoning, wood spirit poisoning, carbinol poisoning, methanol toxicity, methanol intoxication, methanol overdose.

Data derivation. Knowledge is derived primarily from aggregated disease-level sources — clinical toxicology practice guidelines, case series, and mass-poisoning outbreak cohorts (Estonia, Norway, Iran, Malaysia, Libya, Tunisia) — supplemented by individual case reports and controlled animal/primate studies of formate toxicity. It is not a registry/EHR-defined chronic disease.

2. Etiology

Primary cause (environmental/chemical). Ingestion (most common), inhalation, or transdermal absorption of methanol-containing products. There is no genetic causation; this is a xenobiotic intoxication. Common sources (StatPearls NBK482121): - Adulterated/illicit "bootleg" alcoholic beverages — the leading cause of mass-casualty outbreaks worldwide, especially where informal spirits are consumed or during alcohol prohibition. - Windshield washer/wiper fluid, antifreeze (some formulations), carburetor cleaner, gas-line antifreeze, solvents, paint removers/thinners, shellac, duplicating/copy-machine fluid, canned "chafing/heating fuel" (Sterno), perfumes/colognes, hand sanitizers (methanol-contaminated hand sanitizers caused FDA recalls and poisonings in 2020). - Industrial/occupational and inhalational exposure (fuel, laboratory, model-airplane fuel).

Toxic dose. The estimated minimum lethal dose is ~1 g/kg (≈1–2 mL/kg of pure methanol); as little as ~10 mL can cause permanent blindness and ~30 mL can be fatal, though outcome depends heavily on time to treatment and co-ingested ethanol. Blood methanol >20–25 mg/dL generally warrants antidotal treatment (StatPearls NBK482121).

Risk factors. - Behavioral/social: alcohol use disorder, consumption of illicitly produced/counterfeit spirits, suicidal self-poisoning, poverty and alcohol prohibition contexts, pandemic-related disruption of legal alcohol supply (large Iranian outbreaks during COVID-19) (Hassanian-Moghaddam et al., PMC9189800). - Occupational: solvent/fuel handling. - Nutritional: folate deficiency (malnourished, chronic alcoholics) slows formate clearance and worsens toxicity — a modifiable host factor (see §6). - Demographic: adult males predominate in most outbreak cohorts (median age ~32 in the Iran cohort).

Protective factors. - Co-ingested ethanol is strongly protective: ethanol competitively saturates alcohol dehydrogenase (ADH) — for which it has ~10–20× higher affinity than methanol — delaying/blocking formate generation. This is both the mechanistic basis for ethanol antidotal therapy and an explanation for why some heavily co-intoxicated patients present late but with lower formate burden. - Adequate folate status accelerates formate → CO₂ oxidation (see §6). - No well-established germline protective allele; a pharmacogenetic modifier signal exists at ALDH2 (below).

Gene–environment interaction (pharmacogenetic modifier). In acutely methanol-exposed humans, the ALDH2 minor (C, ALDH2*2-associated) allele was over-represented among poisoned patients (46%) versus healthy controls (31%) (odds ratios ~1.9), suggesting reduced-activity ALDH2 modifies susceptibility/outcome, whereas ADH1B variation did not significantly affect susceptibility (Zakharov et al. 2018, PMID:29968299). This is a susceptibility/modifier signal (SUSCEPTIBILITY relationship type), not a causal gene.

3. Phenotypes

Methanol poisoning is a biphasic syndrome. Suggested HPO terms and typical frequencies below (frequencies are qualitative estimates from outbreak cohorts; treat frequency bands cautiously per curation policy).

Early (0–~12 h, "mild inebriation" phase): | Phenotype | HPO suggestion | Notes | |---|---|---| | Inebriation / CNS depression (mild) | HP:0001254 (Lethargy) / HP:0001250 relatives | Often milder than expected for ethanol | | Nausea and vomiting | HP:0002018 (Nausea), HP:0002013 (Vomiting) | Common; GI irritation | | Abdominal pain | HP:0002027 (Abdominal pain) | Can mimic pancreatitis | | Headache, dizziness | HP:0002315 (Headache), HP:0002321 (Vertigo) | |

Latent period (~12–24 h): relatively asymptomatic while formate accumulates — a dangerous window where patients appear well.

Late (~12–72 h, toxic phase): | Phenotype | HPO suggestion | Frequency (qualitative) | |---|---|---| | Visual disturbance — blurred vision, "snowfield"/halo vision, photophobia, decreased acuity, central scotoma | HP:0000504 (Abnormality of vision), HP:0000546 (Retinal degeneration), HP:0000662 (Nyctalopia relatives) | Very frequent; visual sequelae in ~30–40% of survivors (PMC8731680) | | Blindness / severe visual loss | HP:0000618 (Blindness) | Occasional–frequent, often permanent | | Optic disc hyperemia / peripapillary edema → optic atrophy | HP:0000543 (Optic disc pallor), HP:0000648 (Optic atrophy) | Fundoscopic hallmark | | Fixed/dilated, poorly reactive pupils | HP:0000545 relatives; HP:0000577 (Abnormal pupillary function) | Poor prognostic sign | | High-anion-gap metabolic acidosis | HP:0001942 (Metabolic acidosis) | Cardinal lab abnormality (late) | | Tachypnea / Kussmaul hyperventilation | HP:0002098 (Respiratory distress), HP:0002091 (Tachypnea) | Respiratory compensation | | Coma / depressed consciousness | HP:0001259 (Coma) | Severe cases; poor prognosis | | Seizures | HP:0001250 (Seizure) | Severe cases | | Parkinsonism / dystonia (delayed) | HP:0001300 (Parkinsonism), HP:0001332 (Dystonia) | Sequela of putaminal necrosis | | Hypotension / circulatory failure | HP:0002615 (Hypotension) | Terminal; strongly predicts death | | Pancreatitis / elevated amylase | HP:0001733 (Pancreatitis) | Reported complication |

Phenotype characteristics: onset acute/subacute (adult predominant); severity variable (from asymptomatic to fatal), dose- and time-to-treatment-dependent; course episodic-then-progressive in untreated disease; neuro-ophthalmic deficits may be permanent (progressive optic atrophy) or partially recover.

Prognostic phenotype associations (from cohorts): nausea and blurred vision at presentation were paradoxically associated with better prognosis (earlier presentation), whereas absence of blurred vision and hypotension at admission were associated with death; delayed admission and elevated anion gap predicted blindness (Prognosis in a developing setting, PMC11097318).

Quality-of-life impact: permanent visual loss and Parkinsonian motor sequelae substantially impair independent functioning; long-term follow-up documents new-onset neurologic and visual impairment developing even after apparent recovery (Paasma et al. 2009, PMID:19327138).

4. Genetic / Molecular Information

Not applicable as a causal genetic disease. There are no causal genes, pathogenic variants, chromosomal abnormalities, or Mendelian inheritance.

Relevant enzymes/genes (host metabolism, not disease-causing): - ADH1B / ADH1C / ADH1A (alcohol dehydrogenase, class I; HGNC:249, HGNC:250, HGNC:251) — catalyze methanol → formaldehyde; the therapeutic target of fomepizole/ethanol. ADH1B polymorphism does not significantly modify susceptibility (PMID:29968299). - ALDH2 (aldehyde dehydrogenase 2, mitochondrial; HGNC:404) — formaldehyde → formate; the reduced-activity ALDH2*2 allele is a candidate modifier of outcome (PMID:29968299). - ALDH1L1 (cytosolic 10-formyltetrahydrofolate dehydrogenase, FDH; HGNC:3978) — the folate-dependent enzyme oxidizing 10-formyl-THF → THF + CO₂; the only pathway that clears formate in humans and the basis of folate/folinic-acid rescue. Adequate folate + functional FDH protect against toxicity (folate-formate literature). - CAT (catalase) and peroxisomal metabolism contribute to methanol/formaldehyde handling, especially in retina (minor pathway).

Epigenetics / molecular profiling: No established disease-specific methylation/histone signature; transcriptomic/proteomic/metabolomic profiling is not a routine diagnostic feature. The definitive metabolomic biomarker is elevated serum formate.

5. Environmental Information

  • Environmental/toxic factors: methanol (CHEBI:17790) is the sole necessary exposure. Sources as in §2 (illicit spirits, washer fluid, solvents, adulterated sanitizer). CTD indexes methanol/formaldehyde/formic acid toxicant–gene interactions.
  • Lifestyle factors: heavy/illicit alcohol consumption is the dominant behavioral driver; poor nutrition (folate deficiency) worsens outcome.
  • Infectious agents: none (not applicable).
  • Contextual amplifiers: alcohol prohibition, informal alcohol economies, and supply-chain disruptions (e.g., COVID-19 pandemic misinformation that alcohol prevents infection) precipitate large outbreaks (PMC9189800).

6. Mechanism / Pathophysiology

Central causal chain (toxicokinetic → toxicodynamic):

  1. Methanol (CHEBI:17790) is absorbed and distributed in body water; it is only weakly CNS-depressant on its own.
  2. ADH oxidizes methanol → formaldehyde (rate-limiting; NAD⁺→NADH). "Alcohol dehydrogenase oxidizes methanol to formaldehyde, and aldehyde dehydrogenase subsequently oxidizes formaldehyde to formic acid" (StatPearls NBK482121). GO:0004022 (alcohol dehydrogenase activity), GO:0006069 (ethanol/alcohol oxidation).
  3. ALDH2 oxidizes formaldehyde → formic acid/formate (very rapid; formaldehyde does not accumulate). GO:0004029 (aldehyde dehydrogenase activity).
  4. Formate accumulates because human formate clearance (folate-dependent 10-formyl-THF pathway via ALDH1L1/FDH) is slow and saturable — the species difference that makes primates far more sensitive than rodents (PNAS 1985).
  5. Formate inhibits mitochondrial cytochrome c oxidase (Complex IV) → blockade of the electron transport chain → histotoxic (cytotoxic) hypoxia and ATP depletion (Liesivuori & Savolainen 1991). GO:0004129 (cytochrome-c oxidase activity), GO:0006123 (mitochondrial electron transport, cytochrome c to oxygen), GO:0006119 (oxidative phosphorylation).
  6. Downstream amplifiers:
  7. Impaired aerobic respiration → lactic acidosis compounds the direct organic (formic) acidosis → severe high-anion-gap metabolic acidosis (GO:0006099 TCA/energy metabolism disruption).
  8. Acidemia increases the un-ionized (diffusible) fraction of formic acid, enhancing cellular entry — a positive-feedback loop worsening tissue penetration and toxicity.
  9. ETC blockade → increased reactive oxygen species → oxidative stress and apoptosis (Liesivuori & Savolainen 1991). GO:0006915 (apoptotic process), GO:0006979 (response to oxidative stress).
  10. Target-tissue injury:
  11. Optic nerve / retina: the retinal ganglion cells, optic nerve head (prelaminar region), and photoreceptors are highly vulnerable due to high energy demand; histopathology shows axonal vacuolation and edema of the oligodendroglia, optic disc edema → optic atrophy (PMC8731680). Suggested CL terms: CL:0000740 (retinal ganglion cell), CL:0000210 (photoreceptor cell), CL:0000128 (oligodendrocyte), CL:0000031 (neuroblast/neuron relatives); UBERON:0000941 (optic nerve), UBERON:0000966 (retina).
  12. Basal ganglia (putamen): bilateral putaminal necrosis ± hemorrhage is the characteristic CNS lesion, attributed to the region's metabolic vulnerability to formate/ischemia; predilection for putamen (not caudate) helps distinguish it from CO poisoning (Sefidbakht et al., MRI spectrum; putamen necrosis, PMID:9561519). UBERON:0001874 (putamen), UBERON:0002420 (basal ganglion). CL:0000129 (microglia) and neuron loss involved.
  13. Systemic collapse: progressive acidosis, coma, seizures, hypotension, respiratory/circulatory failure → death.

Upstream vs downstream: methanol ingestion and ADH-mediated oxidation are upstream; formate accumulation and Complex IV inhibition are the pivotal node; metabolic acidosis, ROS/apoptosis, optic-nerve and putaminal injury are downstream effectors of clinical morbidity.

Protein dysfunction: the injury is not from a mutant protein but from formate as a reversible inhibitor of cytochrome c oxidase (heme a₃–CuB binuclear center), analogous to cyanide/azide.

Metabolic changes: blocked oxidative phosphorylation, elevated lactate, elevated formate; folate one-carbon pool consumption during formate detoxification.

Immune involvement: secondary sterile inflammation/oxidative injury; no primary autoimmune mechanism.

7. Anatomical Structures Affected

Organ level (primary): - Eye / optic nerve (UBERON:0000970 eye; UBERON:0000941 optic nerve; UBERON:0000966 retina) — primary and most feared target. - Brain, specifically basal ganglia / putamen (UBERON:0000955 brain; UBERON:0002420 basal ganglia; UBERON:0001874 putamen) — bilateral necrosis ± hemorrhage; subcortical white matter can also be involved.

Organ level (secondary/systemic): - Metabolic/whole-body: high-anion-gap metabolic acidosis (blood/plasma). - Cardiovascular (hypotension, circulatory failure), respiratory (compensatory hyperventilation, later failure), gastrointestinal/pancreas (nausea, abdominal pain, pancreatitis), kidney (secondary in severe/shock states), CNS (coma, cerebral edema).

Body systems: nervous (central + special sensory/visual), cardiovascular, respiratory, digestive, and metabolic/acid–base systems.

Tissue/cell level: retinal ganglion cells (CL:0000740), photoreceptors (CL:0000210), optic-nerve oligodendrocytes/myelin (CL:0000128), basal-ganglia neurons; endothelial and glial involvement in hemorrhagic putaminal lesions.

Subcellular level: mitochondria (GO:0005739) — the primary compartment of injury (Complex IV, GO:0005751 mitochondrial respiratory chain complex IV); peroxisomes (retinal methanol metabolism, GO:0005777).

Localization/lateralization: CNS and optic lesions are characteristically bilateral and symmetric.

8. Temporal Development

  • Onset: acute, typically adult. Symptom onset is delayed 12–24 h post-ingestion (longer if ethanol co-ingested), producing a deceptive latent period (StatPearls NBK482121).
  • Progression/stages: (1) early mild inebriation/GI phase; (2) latent asymptomatic phase; (3) toxic phase (visual, acidotic, CNS); (4) severe/terminal phase (coma, seizures, cardiorespiratory collapse). Progression is rapid once acidosis develops.
  • Course pattern: untreated disease is progressive; with early antidote/dialysis it is largely self-limited with recovery. Neuro-ophthalmic damage, once established, may be permanent (progressive optic atrophy; fixed Parkinsonism from putaminal necrosis).
  • Critical window: intervention before or during formate accumulation (ideally within hours, before significant acidosis/visual loss) is decisive; delayed presentation is the strongest driver of blindness and death. Notably, new visual/neurologic deficits can emerge after discharge (Paasma et al. 2009, PMID:19327138).
  • Duration: acute illness resolves over days with treatment; sequelae are lifelong.

9. Inheritance and Population (Epidemiology)

Epidemiology. Occurs as sporadic individual poisonings and epidemic mass-casualty outbreaks. There is no meaningful "prevalence/incidence per 100,000" as a chronic disease; burden is episodic. In the U.S., roughly ~24 methanol-related deaths were reported in 2023 (StatPearls NBK482121). Large outbreaks include: - Estonia 2001: 111 hospitalized; 86 survived (66 without, 20 with sequelae) (Paasma et al. 2009, PMID:19327138). - Iran (COVID-19 era, 2020): hundreds to thousands poisoned across provinces; one linked cohort reported 795 hospitalized, 84 deaths (PMC9189800). - Malaysia (2018) and other outbreaks report case-fatality up to ~55–61% in some pandemic-era series.

Case fatality / morbidity (from cohorts): reported mortality ranges widely (~8% to >60%) depending on time-to-care, availability of antidote/dialysis, and outbreak conditions; e.g., ~23.9% mortality in one series, with visual sequelae in ~33.7% and neurologic sequelae in ~6.2% (prognosis studies, PMC11097318).

Inheritance: Not applicable (acquired). No inheritance pattern, penetrance, expressivity, anticipation, mosaicism, founder effect, consanguinity, or carrier frequency.

Demographics: adult male predominance; associated with alcohol use disorder, low socioeconomic status, and regions with informal/illicit alcohol production or prohibition. Median outbreak age ~30s. Geographic distribution reflects socioeconomic and regulatory context (South/Southeast Asia, Middle East, Eastern Europe, Africa hotspots), not genetics.

10. Diagnostics

Laboratory (core): - Serum methanol concentration by gas chromatography — definitive; treat at >20–25 mg/dL (StatPearls NBK482121). LOINC: methanol [Mass/volume] in serum/plasma. - Elevated osmolar/osmolal gap early (parent alcohol present; >~10–25 mOsm/kg) that normalizes as methanol is metabolized. LOINC: osmolality serum. - High anion-gap metabolic acidosis later (formate). Arterial blood gas: low pH, low bicarbonate. Anion gap and acidosis are late and correlate with formate. - Serum/plasma formate — best correlate of toxicity/acidosis but not widely available. - Ancillary: elevated lactate, elevated amylase/lipase (pancreatitis), electrolytes/renal function.

Important diagnostic pitfall: early presenters may have an elevated osmolar gap without acidosis; late presenters may have severe acidosis with a near-normal osmolar gap (methanol already metabolized). Serial BMP/ABG every 2–4 h is advised, with 16–24 h observation (StatPearls NBK482121).

Imaging (prognostic, not primary diagnostic): - CT/MRI: bilateral putaminal necrosis ± hemorrhage, subcortical white-matter and optic-nerve changes; putamen-predominant (vs caudate in CO poisoning) plus optic atrophy is nearly pathognomonic (MRI spectrum, ScienceDirect; PMID:9561519). RadLex: putaminal necrosis/hemorrhage.

Ophthalmologic: funduscopy (optic disc hyperemia, peripapillary edema early; optic atrophy late), pupillary reactivity (fixed/dilated = poor prognosis); OCT and visual-evoked potentials for follow-up.

Genetic testing: Not applicable for diagnosis (no causal gene). Pharmacogenetic ALDH2 genotyping is a research modifier, not clinical.

Clinical criteria / differential diagnosis: high-anion-gap metabolic acidosis (MUDPILES) differentials — ethylene glycol poisoning (calcium-oxalate crystals, renal failure, no visual loss), diabetic/alcoholic/lactic ketoacidosis, uremia, salicylate, isopropanol (ketosis without acidosis), paraldehyde. Osmolar-gap + anion-gap pattern, visual symptoms, and putaminal imaging distinguish methanol.

Screening: no population screening; public-health outbreak surveillance of adulterated alcohol is the operative "screening" mode.

11. Outcome / Prognosis

  • Mortality: highly variable (~8% to >60%), driven by time to treatment, severity of acidosis (pH), coma, and antidote/dialysis availability (PMC11097318; PMC9189800).
  • Key adverse prognostic factors: low arterial pH (<7.0–7.2), coma or seizures on presentation, hypotension (in some cohorts, all hypotensive-on-admission patients died), abnormal pupillary reactivity, high formate, delayed presentation (PMC8731680; PMC11097318).
  • Visual morbidity: persistent visual sequelae in ~30–40% of survivors; initial severity predicts long-term visual outcome; some remyelination-related recovery over ~2 years (PMC8731680).
  • Neurologic morbidity: Parkinsonism, dystonia, cognitive deficits from bilateral putaminal necrosis; delayed encephalopathy. New deficits can appear post-discharge (Paasma et al. 2009, PMID:19327138).
  • Recovery potential: excellent if treated before significant acidosis/visual loss; established optic atrophy and putaminal necrosis are largely irreversible.
  • Prognostic biomarkers: admission pH/bicarbonate, formate, methanol level, GCS, and hemodynamic status; risk-prediction nomograms for in-hospital mortality have been developed (PMC11617918).

12. Treatment

The strategy is: (1) block toxic-metabolite formation (ADH inhibition), (2) correct acidosis, (3) enhance formate elimination (dialysis + folate), (4) supportive care.

Antidotes — ADH inhibition (MAXO:0000001 therapeutic intervention / MAXO pharmacotherapy): - Fomepizole (4-methylpyrazole) — first-line preferred antidote. Binds ADH with affinity ~8,000× greater than ethanol, halting methanol→formaldehyde. Dosing: loading 15 mg/kg IV, then 10 mg/kg q12h ×4 doses, then 15 mg/kg q12h (autoinduction), until methanol <20–25 mg/dL and acidosis resolves; q4h or post-dialysis dosing during hemodialysis (StatPearls NBK482121). Landmark efficacy/safety trial: Brent et al., NEJM 2001 (Methylpyrazole for Toxic Alcohols Study Group) (NEJM 2001). CHEBI: fomepizole (CHEBI:47519). Therapeutic agent binds ADH1B (target enzyme). - Ethanol — alternative when fomepizole unavailable; competitive ADH substrate. Target serum ethanol 100–120 mg/dL (IV 10%: ~8 mL/kg load then 1–2 mL/kg/h; oral 50%: 2 mL/kg load then 0.2–0.4 mL/kg/h); requires frequent level monitoring, causes intoxication/hypoglycemia, harder to titrate (StatPearls NBK482121). CHEBI:16236 (ethanol).

Extracorporeal removal — hemodialysis (MAXO:0000059 hemodialysis / renal replacement): - Removes both methanol and formate and corrects acidosis; dramatically shortens methanol half-life (from ~52–70 h with fomepizole alone to ~2.5 h with dialysis). - EXTRIP / AACT indications: severe metabolic acidosis, coma or seizures, visual deficits, renal impairment, or high methanol concentration (>~50 mg/dL without fomepizole; >~70 mg/dL with fomepizole), or evidence of end-organ injury (EXTRIP/AJKD Core Curriculum; AACT Practice Guidelines, Barceloux et al.). Intermittent HD is generally preferred over continuous RRT in mass-casualty settings (PMC5519513).

Acidosis correction: - IV sodium bicarbonate for severe metabolic acidosis; raising pH also traps formate in ionized (less diffusible) form, reducing tissue penetration, and improves formate renal clearance (MAXO/pharmacotherapy). CHEBI:32139 (bicarbonate).

Enhancing formate elimination (folate cofactor rescue): - Folinic acid (leucovorin) — preferred (bypasses dihydrofolate reductase), typically 1 mg/kg (up to ~50 mg) IV q4–6h; folic acid if folinic unavailable. Provides the tetrahydrofolate substrate for 10-formyl-THF dehydrogenase (ALDH1L1) to oxidize formate → CO₂. Folate deficiency potentiates and folate repletion prevents/reverses methanol toxicity in primates (PNAS 1985; folates & visual sequelae, ScienceDirect). CHEBI: folinic acid (CHEBI:15636), folic acid (CHEBI:27470). MAXO: dietary/vitamin supplementation.

Supportive care (MAXO:0000950 supportive care): airway/ventilation, IV fluids with dextrose and thiamine (CHEBI:26948), electrolyte management, seizure control, hemodynamic support.

Investigational/adjunctive for optic injury: high-dose IV methylprednisolone (e.g., 1 g/day ×3–4 days) reported effective in >80% of early-treated cases; erythropoietin neuroprotection and near-infrared photobiomodulation (670 nm) show promise in animal/pilot studies (PMC8731680). These are not standard of care.

Pharmacogenomics: ALDH2 genotype may modify outcome (research); no genotype-guided dosing exists.

13. Prevention

  • Primary prevention (population/public-health, the dominant lever): regulation and quality control of alcoholic beverages; suppression of illicit/counterfeit spirit production; denaturing/formulation and product labeling (though methanol denaturing is itself a hazard); consumer warnings on washer fluid, solvents, and hand sanitizer; removal of methanol-contaminated hand sanitizers (FDA 2020 actions); rapid outbreak response (alerting, stockpiling fomepizole/ethanol, ensuring dialysis capacity) (StatPearls NBK482121; WHO methanol-poisoning technical guidance).
  • Secondary prevention: early recognition and rapid antidote/dialysis in exposed individuals; poison-control triage; screening co-exposed people during known outbreaks (shared source).
  • Tertiary prevention: aggressive acidosis correction and extracorporeal removal to prevent blindness/CNS injury; ophthalmologic and neurologic follow-up for sequelae.
  • Behavioral interventions: alcohol-use-disorder treatment; public education (especially countering misinformation, e.g., "drinking alcohol prevents COVID").
  • Environmental interventions: occupational solvent-exposure controls (ventilation, PPE, exposure limits).
  • Counseling / immunization / prophylactic medication: genetic counseling and vaccination not applicable; no prophylactic drug.

14. Other Species / Natural Disease

  • Taxonomy / susceptibility: methanol toxicity is species-dependent and driven by hepatic tetrahydrofolate–dependent formate-oxidation capacity. Primates (including humans, NCBITaxon:9606) clear formate slowly and are highly susceptible; rodents (mouse NCBITaxon:10090, rat NCBITaxon:10116) oxidize formate rapidly and are relatively resistant, developing acidosis/ocular injury only under folate deficiency or folate-blockade (PNAS 1985).
  • Veterinary/natural disease: accidental methanol exposure occurs in companion and production animals, but classic optic/putaminal syndrome is a primate phenomenon; ethylene glycol is the far more common toxic-alcohol veterinary poisoning.
  • Comparative biology / evolutionary conservation: the ADH→ALDH oxidation and the folate one-carbon formate-clearance pathway (ALDH1L1/FDH) are evolutionarily conserved; the human phenotype reflects a quantitative (slow formate clearance), not qualitative, difference.
  • Zoonotic potential / transmission: none (chemical toxicity, not transmissible).

15. Model Organisms

  • Non-human primates (macaque/monkey): the gold-standard model reproducing human formate accumulation, metabolic acidosis, and ocular/optic toxicity; used to establish that formate (not methanol/formaldehyde) is the toxic agent and that folate modulates toxicity (PNAS 1985). MODEL_ORGANISM evidence.
  • Folate-deficient / folate-blocked rodents and folate-deficient young swine: engineered to slow formate clearance so rodents recapitulate primate-like formate toxicokinetics; used for formate pharmacokinetics and antidote studies (formate PK in folate-deficient swine, ScienceDirect).
  • Rat / rabbit ocular-toxicity models: for retinal/optic-nerve mitochondrial injury, photoreceptor vulnerability, and photobiomodulation/neuroprotection studies.
  • In vitro / cellular: isolated mitochondria and cell lines to characterize formate inhibition of cytochrome c oxidase (Complex IV) and ROS generation (IN_VITRO evidence) (Liesivuori & Savolainen 1991).
  • Genetic models: no knockout "disease model" per se; Aldh1l1 (FDH) and folate-pathway perturbations are the closest genetic modifiers used to sensitize animals.
  • Model limitations: rodents require artificial folate deficiency to mimic human sensitivity; no single model fully captures the human latent period + delayed bilateral putaminal necrosis; primate models are ethically/logistically constrained.
  • Resources: MGI/RGD (Adh, Aldh2, Aldh1l1 orthologs), Alliance of Genome Resources, Comparative Toxicogenomics Database (methanol/formaldehyde/formic acid).

Consolidated Ontology Term Suggestions

Key References (PMID/DOI)

  1. StatPearls, "Methanol Toxicity" — NBK482121 — comprehensive clinical review (dose, metabolism, dosing, prognosis). https://www.ncbi.nlm.nih.gov/books/NBK482121/
  2. Brent J, McMartin K, Phillips S, et al. Fomepizole for the Treatment of Methanol Poisoning. N Engl J Med. 2001;344(6):424–429 (Methylpyrazole for Toxic Alcohols Study Group). https://www.nejm.org/doi/full/10.1056/NEJM200102083440605
  3. Barceloux DG, et al. AACT Practice Guidelines on the Treatment of Methanol Poisoning. J Toxicol Clin Toxicol. 2002;40(4):415–446. https://www.tandfonline.com/doi/abs/10.1081/CLT-120006745
  4. Liesivuori J, Savolainen H. Methanol and formic acid toxicity: biochemical mechanisms. Pharmacol Toxicol. 1991 — Complex IV inhibition, histotoxic hypoxia, ROS/apoptosis. https://physoc.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1600-0773.1991.tb01290.x
  5. Paasma R, Hovda KE, Jacobsen D. Methanol poisoning and long term sequelae – a six years follow-up after a large methanol outbreak. BMC Clin Pharmacol. 2009;9:5. PMID:19327138. https://pubmed.ncbi.nlm.nih.gov/19327138/
  6. Zakharov S, et al. ALDH2 polymorphism affects the outcome of methanol poisoning in exposed humans. 2018. PMID:29968299. https://pubmed.ncbi.nlm.nih.gov/29968299/
  7. Methanol-induced optic neuropathy: a still-present problem. PMC8731680 (PMID:34988610) — mechanism, ~30–40% persistent visual sequelae, adjunctive therapies. https://pmc.ncbi.nlm.nih.gov/articles/PMC8731680/
  8. MRI spectrum in 58 methanol-intoxication patients (long-term visual/neurologic correlation), Eur J Radiol — putaminal necrosis + optic-nerve enhancement. https://www.sciencedirect.com/science/article/pii/S0378603X16300936
  9. Necrosis and haemorrhage of the putamen in methanol poisoning shown on MRI. PMID:9561519. https://pubmed.ncbi.nlm.nih.gov/9561519/
  10. Hassanian-Moghaddam H, et al. Methanol poisoning hospital admissions/mortality in Iranian adults during COVID-19. PMC9189800. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189800/
  11. Prognosis of Methanol Poisoning in a Developing Setting. PMC11097318 — mortality/sequelae, prognostic factors. https://pmc.ncbi.nlm.nih.gov/articles/PMC11097318/
  12. Risk-prediction nomogram for in-hospital mortality in acute methanol poisoning. PMC11617918. https://pmc.ncbi.nlm.nih.gov/articles/PMC11617918/
  13. EXTRIP / nephrologist role in poisoning (Core Curriculum 2022), Am J Kidney Dis — hemodialysis thresholds and indications. https://www.ajkd.org/article/S0272-6386%2821%2900796-4/fulltext
  14. Species difference: role of hepatic tetrahydrofolate in methanol/formate toxicity. PNAS 1985;82:3854. https://www.pnas.org/doi/pdf/10.1073/pnas.82.11.3854
  15. Acute methanol poisonings: folates administration and visual sequelae. Clin Toxicol/relevant. https://www.sciencedirect.com/science/article/abs/pii/S1214021X14000660

Evidence-source tagging guidance for curation: most clinical claims are HUMAN_CLINICAL (outbreak cohorts, case series, guidelines); the Complex IV/ROS mechanism includes IN_VITRO biochemical data; primate/rodent/swine formate-toxicity and folate-modulation studies are MODEL_ORGANISM; risk-prediction nomograms are HUMAN_CLINICAL (some COMPUTATIONAL modeling on clinical data). Per the dismech DR-verification SOP, each PMID and its snippet must be independently fetched and substring-verified (just fetch-reference PMID:XXXX → just validate-references) before committing — the quotes and figures above are research leads, not pre-validated evidence snippets.

Notable data gaps / not applicable: no causal gene, inheritance, penetrance, carrier frequency, or chromosomal abnormality (acquired poisoning); no established disease-specific epigenetic or omics diagnostic signature; formate assays and pharmacogenetic (ALDH2) testing remain research/reference-lab tools rather than routine clinical diagnostics.